Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for Endocrine Agents Miscellaneous, specifically for the May 2026 P&T Committee Meeting. It includes two main appendices: the Blanket Purchase Agreement (BPA) Appendix and the Additional Discount Program (ADP) Appendix, covering both non-FAMP and WAC discounts.

• BPA Appendix: Lists NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing per NDC and per unit for Uniform Formulary and Non-Formulary scenarios. It also includes class notes regarding review by the P&T Committee, potential Prior Authorization (PA), and special reimbursement methods.
• ADP Appendix (non-FAMP & WAC): Details TRICARE Retail Refund information, including Non-FAMP Price, Additional Offered Refund, Current Annual Federal Ceiling Price (FCP), Standard Refund, and Total Calculated Retail Refund. It also outlines class notes similar to the BPA, emphasizing P&T Committee review, PA, and potential preferential status or exclusion.
• Quotes Due: April 27, 2026, for all scenarios.
• P&T Committee Meeting: May 6-7, 2026.

This document is crucial for bidders offering pharmaceutical products within the Endocrine Agents Miscellaneous class. It outlines the specific pricing structures (BPA, non-FAMP discount, WAC discount), formulary categories (Tier 2, Tier 3), and deadlines for submitting quotes. Bidders must review the pricing scenarios and class notes to understand how their products will be evaluated and potentially reimbursed, and to ensure timely submission of quotes and required documentation (Quote Review Checklist, signature pages).

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for "Targeted Immunomodulatory Biologics" within the "Interleukin 23" subclass, relevant for the May 2026 DoW P&T Meeting. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Program (ADP) with non-FAMP discounts, and ADP with WAC discounts.

• BPA Appendix: Lists formulary scenarios and requires quotes by April 27, 2026. It specifies that prices per unit will be the same for all package sizes within a given dispensing venue. Several scenarios indicate "NO QUOTE" for specific conditions.
• ADP (non-FAMP Discount) Appendix: Details TRICARE retail refund calculations based on Non-FAMP prices and additional offered refunds. It outlines formulary scenarios (Tier 2 and Tier 3) and requires quotes by April 27, 2026.
• ADP (WAC Discount) Appendix: Outlines calculations for refunds based on Wholesale Acquisition Cost (WAC) discounts. It also details formulary scenarios and requires quotes by April 27, 2026.
• Formulary Notes: Across all sections, notes indicate that Prior Authorization (PA) may apply. Step therapy and biosimilar step therapy addendums are detailed, with specific rules regarding grandfathering. The P&T Committee may consider removing step preference for certain indications and may designate agents without submitted RFQs as non-step preferred.

This document is crucial for manufacturers and vendors interested in providing "Targeted Immunomodulatory Biologics" (Interleukin 23 subclass) to TRICARE. Bidders must review the pricing structures (BPA, non-FAMP, WAC), understand the formulary scenarios, step therapy requirements, and potential P&T Committee decisions. The quote due date is April 27, 2026. Manufacturers are reminded to submit fully executed signature pages with their quotes.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for "Metabolic Agents - Miscellaneous" and "Replacement Enzymes" for the May 2026 P&T Meeting. It includes Blanket Purchase Agreement (BPA) appendices and Additional Discount Program (ADP) appendices, detailing pricing scenarios based on Uniform Formulary (UF) and Non-FAMP/WAC discounts.

• BPA Appendix: Lists NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing per NDC and per unit for Uniform Formulary and Non-Formulary scenarios. It indicates "NO QUOTE" for certain entries and highlights cells that require confirmation of intent not to submit a quote.
• ADP (non-FAMP Discount) Appendix: Details pricing based on Non-FAMP (non-Federal Ceiling Price) and includes columns for Non-FAMP Price, Additional Offered Refund, Current Annual Federal Ceiling Price, Standard Refund, and Total Calculated Retail Refund. It also outlines formulary scenarios (Tier 2, Tier 3) and requires confirmation if cells are highlighted red.
• ADP (WAC Discount) Appendix: Similar to the non-FAMP discount, this section details pricing based on Wholesale Acquisition Cost (WAC), including WAC Price, WAC Discount, and Total Calculated Retail Refund. It also covers formulary scenarios and requires confirmation for highlighted cells.
• Class Notes: Applicable to all sections, these notes mention that agents will be reviewed at the P&T Committee meeting, Prior Authorization (PA) may apply, and agents may be considered for special reimbursement methods or exclusion from the TRICARE pharmacy benefit program. Agents not submitted or selected for RFQ may be designated non-step preferred.
• Notes to Manufacturers: Emphasizes the need to submit the Quote Review Checklist and fully executed signature pages along with quote information.
• Quotes Due: April 27, 2026.

This document is crucial for manufacturers and suppliers of "Metabolic Agents - Miscellaneous" and "Replacement Enzymes." It outlines the specific pricing structures, discount programs (non-FAMP and WAC), and formulary scenarios relevant to the TRICARE pharmacy benefit program. Bidders must review the pricing, understand the refund calculations, and adhere to the submission requirements and deadlines (April 27, 2026) to participate in this opportunity. The "NO QUOTE" indicators and red highlighting instructions are critical for proper response.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for Growth Stimulating Agents, relevant for the May 2026 P&T Committee Meeting. It includes Blanket Purchase Agreement (BPA) Appendices and Additional Discount Program (ADP) Appendices for both non-FAMP and WAC discounts.

• BPA Appendix: Details pricing for the Uniform Formulary (UF) class of Growth Stimulating Agents. It outlines scenarios for "Uniform Formulary Before Step Therapy" and "Non-Formulary After Step Therapy," with a quote due date of April 27, 2026. Manufacturers are reminded to submit the Quote Review Checklist and executed signature pages.
• ADP (non-FAMP Discount) Appendix: Provides details on additional discounts for Growth Stimulating Agents under the Additional Discount Program, calculated based on non-FAMP (non-Federal Average Manufacturer Price) and Federal Ceiling Price (FCP). It specifies scenarios for "Tier 2 Before Step" and "Tier 3 After Step" therapies, with a quote due date of April 27, 2026.
• ADP (WAC Discount) Appendix: Outlines additional discounts based on Wholesale Acquisition Cost (WAC) for Growth Stimulating Agents. Similar to the non-FAMP appendix, it details scenarios for "Tier 2 Before Step" and "Tier 3 After Step" therapies, with a quote due date of April 27, 2026.
• Formulary Notes: Applicable across all sections, these notes indicate that Prior Authorization (PA) may apply. Agents may be subject to special reimbursement methods to encourage high-value products. Step therapy requirements are detailed, and agents with unsubmitted or unselected RFQs may be designated non-step preferred. A scenario is noted where Uniform Formulary and/or Tier 2 before step therapy may be considered if ingredient cost is ≤ $1500 average per 4 weeks of therapy.

This document is crucial for vendors offering Growth Stimulating Agents. It provides the specific pricing structures, discount programs (non-FAMP and WAC), formulary placement scenarios, and step therapy guidelines that will be considered by the P&T Committee. Bidders must pay close attention to the "Quotes due" date of April 2026-04-27 and ensure all required documentation, including pricing and discount information, is submitted correctly to be considered for the formulary.

Form / Attachment / Pricing Sheet

This document, titled "Price Appendix FAQ," provides frequently asked questions and instructions for completing pricing appendices related to an opportunity. It clarifies how bidders should input pricing information for different categories, including BPA (Best Price Available), ADP (non-FAMP Discount), and ADP (WAC Discount).

• BPA: Instructions on filling out yellow cells, auto-population of fields based on Package Size, and how a red highlight indicates no quote submission for a condition set. It also details how Price per Unit is calculated.
• ADP (non-FAMP Discount): Guidance on entering non-FAMP prices and Current Annual Federal Ceiling Prices, with auto-population for subsequent rows. It explains the calculation for Total Calculated Refund and notes that a 0.0000% Additional offered refund will highlight red.
• ADP (WAC Discount): Clarifies that WAC is used for products without a FCP. Similar to ADP (non-FAMP), it outlines auto-population for WAC prices and how a 0.0000% WAC Discount will highlight red. The Total Calculated Retail Refund per Package is auto-calculated.
• General Instructions: For all sections, bidders are instructed to read "Formulary Notes" at the top of the spreadsheet for P&T committee decision-making processes. Bidders only need to fill out tables for their specific NDCs (up to 10). For more than 10 NDCs, bidders should contact the POCs listed in the RFQ document. Contact information for questions or concerns is also provided.

This document is crucial for bidders as it directly guides the preparation and submission of pricing information. Understanding these instructions is essential for accurate proposal development and to ensure compliance with the government's pricing requirements. It clarifies how to input data, what fields are auto-calculated, and how to indicate non-participation in certain pricing scenarios.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for "Metabolic Agents - Miscellaneous" for the May 2026 P&T Committee Meeting. It includes two main sheets: 'BPA' (Blanket Purchase Agreement Appendix) and 'ADP' (Additional Discount Program Appendix), with sub-sections for non-FAMP and WAC discounts.

• P&T Committee Meeting: May 6-7, 2026
• Quotes Due: April 27, 2026
• Class Note(s): Agents in this class will be reviewed by the P&T Committee. Prior Authorization (PA) may apply. Agents may be considered for special reimbursement methods or complete exclusion from the TRICARE pharmacy benefit program. Agents not submitted or selected may be designated non-step preferred.
• BPA Sheet: Lists "NO QUOTE" for all listed scenarios, indicating no current pricing is provided for these specific formulary categories.
• ADP (non-FAMP & WAC) Sheets: Detail calculations for retail refunds based on Non-FAMP (non-Federal Acquisition Price) and WAC (Wholesale Acquisition Cost) discounts. These sheets outline how refunds are calculated and mention that the quoted discount percentage remains static, but the underlying non-FAMP or FCP may change annually.
• Notes to Manufacturers: Emphasize the need to submit the Quote Review Checklist and fully executed signature pages along with quote information.

This document is crucial for potential bidders offering metabolic agents. It outlines the submission deadline for quotes (April 27, 2026) and provides context on how pricing and discounts (FAMP, WAC) will be evaluated for formulary inclusion. The "NO QUOTE" entries in the BPA sheet suggest a specific focus on discount programs for these agents. Manufacturers should pay close attention to the refund calculation methodologies and the P&T Committee review process.

Forms / Attachments / Pricing Sheets

This document contains price lists and additional discount program appendices related to Antilipidemics-1, specifically the PCSK-9 subclass, for the May 2026 P&T Committee Meeting. It outlines pricing structures and discount programs relevant to potential bidders.

• BPA Sheet: Details Uniform Formulary (UF) Blanket Purchase Agreement (BPA) pricing for PCSK-9 subclass drugs. It includes notes on Prior Authorization (PA), formulary considerations based on ingredient cost (e.g., <$250 or >$250 per 30-day supply), and step therapy addendum grandfathering. Quotes are due April 27, 2026.
• ADP (non-FAMP Discount) Sheet: Outlines the Additional Discount Program (ADP) for non-FAMP (Federal Ceiling Price) discounts. It details calculations for total calculated retail refunds and specifies that the quoted additional refund percentage remains static, but the annual non-FAMP may change yearly. Applicable for Tier 2 and Tier 3 'After Step' formulary scenarios.
• ADP (WAC Discount) Sheet: Details the ADP for Wholesale Acquisition Cost (WAC) discounts. It explains that WAC is used for products without an FCP and can be applied to covered drugs. The WAC discount percentage is static for the agreement's life. Applicable for Tier 2 and Tier 3 'After Step' formulary scenarios.

This document is crucial for bidders as it provides the pricing framework, discount structures, and key dates (quotes due April 27, 2026) for supplying PCSK-9 subclass antilipidemic drugs. Understanding these pricing and discount mechanisms is essential for preparing competitive quotes and proposals. The document also clarifies formulary considerations and prior authorization requirements that may impact product selection and pricing strategies.

Other / Unclassified

This document outlines the process for the formulary placement of newly FDA-approved innovator drugs within the TRICARE Pharmacy Benefits Program. It references a Final Rule published in the Federal Register on July 27, 2015, effective August 26, 2015, which grants the Pharmacy and Therapeutics (P&T) Committee up to 120 days to recommend tier placement.

• Drug Evaluation: The P&T Committee evaluates FDA-approved medications under specific biologic license applications (BLA) or new drug applications (NDA) types (Type 1, 2, 3, 4), and may consider other NDA chemical types.
• Pending Status: Drugs approved on or after August 26, 2015, will initially be assigned a pending status and treated as non-formulary.
• Meeting Schedule: Drugs approved 30 days or less before a P&T Committee meeting will be considered at the subsequent quarterly meeting. The DHA Director has final approval authority.
• Pricing & Solicitations: The government will solicit Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (UF ADP) quotes. Manufacturers will have three solicitation windows to submit price concessions prior to the meeting.
• Tier Designation: Drugs will be designated for Tier 1, 2, 3, or 4/Not Covered based on clinical and cost-effectiveness information available at the quarterly meeting.
• Information Posting: Drugs to be reviewed will be posted on health.mil/pandt approximately 30 days before the meeting.
• Distribution and Pricing Agreements (DAPA): Pharmaceutical manufacturers are not obligated to obtain a DAPA, but information on establishing one can be obtained from the Defense Logistics Agency (DLA).
• MTF Availability: Innovator drugs are generally designated as Tier 3 and not available at Military Treatment Facilities (MTFs) unless medical necessity criteria are met, in which case they may be available at a 2nd tier copay.
• Presentations: DoD will not entertain innovator drug clinical presentations due to the volume of newly approved drugs.

Solicitation / RFP / RFQ

This Request for Quotation (RFQ) is for pharmaceutical agents to be considered for placement on the Department of War (DoW) Uniform Formulary (UF). The DoW is required by law to establish an effective and efficient pharmacy benefits program for the Military Health System (MHS). This process involves the DoW Pharmacy and Therapeutics (P&T) Committee considering the clinical and cost-effectiveness of pharmaceutical agents.

• Manufacturers have the opportunity to submit offers that reduce DoW costs for agents.

• Quotes are sought for two instruments: Uniform Formulary Blanket Purchase Agreements (UF BPA) for Military Treatment Facilities (MTFs) and TRICARE Mail Order Pharmacy (TMOP), and Uniform Formulary Additional Discount Program (UF ADP) for refunds applicable to the TRICARE retail network.

• Quotes must include all NDC-11 numbers for the relevant class, and a NDC Price List.

• Pricing must be consistent across all package sizes for a given dosage form and strength.

• UF BPA price quotes are valid for 180 days.

• UF ADP refund quotes are contingent upon agents being placed on the generic (1st tier) or formulary (2nd tier) of the DoW UF.

• The agreement period for UF BPA and UF ADP is until the drug class is reevaluated or terminated.

• RFQ Dates:

  • Posting Date: April 10, 2026
  • Pre-Quotation Teleconference: April 15, 2026
  • Quotes Due: April 27, 2026, 12:00 PM CST
  • Responses to Clinical Questions Due: April 27, 2026
  • P&T Committee Meeting: May 6-7, 2026

• Submission Steps: Download Utilization Dataset and NDC Price List, complete applicable pages and appendices, and submit signed quotes and NDC Price List to the RFQ Point of Contact.

• Evaluation: The P&T Committee will consider clinical and cost-effectiveness, including UF BPA price quotes and UF ADP refund quotes, when recommending agents for the UF and for cost-share tier classification (generic, brand, or non-formulary).

• Not specified in the provided sections.

• A pre-quotation teleconference will be held on April 15, 2026.

• One-on-one appointments with the Industry Technical Liaison are available upon request.

• The DoW reserves the right to reject or decline specific formulations or NDC-11s.

• Companies must have an existing FSS contract / Interim Agreement for quoted agents.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for ADHD Agents (Stimulants) relevant to the May 2026 P&T Meeting. It includes Blanket Purchase Agreement (BPA) Appendices and Additional Discount Program (ADP) Appendices, detailing pricing structures based on Non-FAMP (Federal Ceiling Price) and WAC (Wholesale Acquisition Cost) discounts.

• BPA Appendices: Outline pricing per NDC for ADHD Stimulants, including Uniform Formulary and Non-Formulary scenarios. Notes indicate that prices are per unit of measure and consistent across package sizes. Specific scenarios (1-10) are listed with placeholder values, indicating where quotes are expected.
• ADP Appendices (Non-FAMP & WAC): Detail refund calculations based on Non-FAMP and WAC pricing. These sections specify how "Total Calculated Retail Refund" is determined and include notes on Prior Authorization (PA) and Step Therapy.
• Class Notes: Applicable to all sections, these notes explain potential Prior Authorization requirements, tier designations for new agents, and the P&T Committee's role in recommending preferential status or exclusion.
• Manufacturer Notes: Remind vendors to submit the Quote Review Checklist and executed signature pages.

This document is crucial for vendors providing ADHD Stimulants. It outlines the pricing structure, discount programs (Non-FAMP and WAC), and refund calculations that will be applied. Bidders must pay close attention to the "Quotes due" date of April 27, 2026, and ensure their submissions align with the specified formulary scenarios and pricing requirements. The document also highlights potential policy considerations such as Prior Authorization and Step Therapy, which may affect product utilization and reimbursement.

Forms / Attachments / Pricing Sheets

This document contains price lists and additional discount program appendices related to Skeletal Muscle Relaxants and Combinations for the May 2026 P&T Committee Meeting. It outlines pricing structures and discount programs relevant to potential bidders.

• BPA Sheet: Lists Uniform Formulary (UF) NDC Price List for Skeletal Muscle Relaxants and Combinations. Includes P&T Committee Meeting dates (May 6-7, 2026) and quotes due date (April 27, 2026). Notes indicate that agents will be reviewed by the P&T Committee, and Prior Authorization (PA) may apply. It also mentions potential for special reimbursement methods and exclusion from the TRICARE pharmacy benefit program. Manufacturers are reminded to submit the Quote Review Checklist and signature pages.
• ADP (non-FAMP Discount) Sheet: Details the UF ADP Appendix for the May 2026 P&T Meeting. It outlines calculations for TRICARE Retail Refund based on non-FAMP (non-Federal Acquisition Regulation Part 13) prices and additional offered refunds. It specifies that the quoted additional refund percentage remains static, but the calculated refund may change annually.
• ADP (WAC Discount) Sheet: Details the UF ADP Appendix for the May 2026 P&T Meeting, focusing on discounts based on Wholesale Acquisition Cost (WAC). It explains that WAC is used for products without an FCP and can be applied to covered drugs. The WAC discount percentage is static for the agreement's life.

This document is crucial for bidders offering Skeletal Muscle Relaxants and Combinations. It provides the framework for pricing, discount calculations (both non-FAMP and WAC), and submission deadlines (April 27, 2026). Bidders must understand these pricing and discount structures to prepare accurate quotes and proposals. The document also highlights important considerations such as potential Prior Authorization, P&T Committee review, and specific submission requirements (Quote Review Checklist, signature pages).

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for Targeted Immunomodulatory Biologics, specifically Interleukin 1 (IL-1), Interleukin 6 (IL-6), and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4). It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Programs (ADP) with non-FAMP discounts, and ADP with WAC discounts.

• BPA Appendix: Lists drug information, formulary scenarios, and pricing per NDC for Military Treatment Facility & Mail Order.
• ADP (non-FAMP Discount) Appendix: Details TRICARE Retail Refund calculations based on non-FAMP prices and additional offered refunds.
• ADP (WAC Discount) Appendix: Outlines refund calculations based on Wholesale Acquisition Cost (WAC) prices.
• Formulary Notes: Applicable to all sections, these notes detail potential Prior Authorization (PA), special reimbursement methods, step therapy addendums (including biosimilar considerations), and the P&T Committee's role.
• Quotes Due: April 27, 2026.
• P&T Committee Meeting: May 6-7, 2026.

This document is crucial for bidders providing pharmaceutical agents within the specified classes. It outlines the pricing structures, discount programs, and formulary requirements that will govern the Blanket Purchase Agreement. Bidders must review the relevant appendices (BPA, ADP non-FAMP, ADP WAC) to understand pricing expectations, refund calculations, and step therapy protocols. The "Quotes due" date is a critical deadline for submission. Manufacturers are reminded to submit the Quote Review Checklist and executed signature pages.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for "Metabolic Dysfunction Agents - Weight Loss Agents" for the May 2026 P&T Committee Meeting. It includes Blanket Purchase Agreement (BPA) appendices and Additional Discount Program (ADP) appendices, detailing pricing structures based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC).

• BPA Appendices: List NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing per unit for Military Treatment Facility & Mail Order. Scenarios include Uniform Formulary and Non-Formulary.
• ADP (non-FAMP Discount) Appendices: Detail TRICARE Retail Refund calculations based on Non-FAMP Price, Additional Offered Refund, Current Annual Federal Ceiling Price, and Standard Refund.
• ADP (WAC Discount) Appendices: Detail TRICARE Retail Refund calculations based on WAC Price and WAC Discount.
• Class Notes: Include information on Prior Authorization (PA), potential for special reimbursement methods, and Step Therapy requirements.
• Notes to Manufacturers: Emphasize the need to submit the Quote Review Checklist and fully executed signature pages.
• Quotes Due: April 27, 2026.

This document is crucial for bidders to understand the pricing structure, discount programs, and formulary status for weight loss medications. It outlines the specific data required for quotes, including various pricing scenarios and refund calculations. Bidders must pay close attention to the "Quotes due" date and the required submission documents. The "Formulary Notes" and "Step Therapy Addendum" provide critical context regarding potential reimbursement and usage policies that may affect product selection and pricing strategies.